Format

Send to

Choose Destination
See comment in PubMed Commons below
J Nippon Med Sch. 2009 Feb;76(1):4-8.

Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents.

Author information

1
Division of Pulmonary Medicine, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. agemma@nms.ac.jp

Abstract

Little was known about drug-induced interstitial lung disease (ILD) when acute ILD-type events developed in several Japanese patients treated with gefitinib. A better understanding of drug-induced ILD is required, including more reliable data about the incidence of events associated with different treatments and identification of the risk factors for this type of ILD. Recent advances in imaging, molecular examination, and pathology have been used in postmarketing surveillance studies designed and conducted by an independent academic team to define the risk and to increase the amount of evidence about ILD related to various molecularly targeted anticancer agents. These studies may shed light on the underlying mechanisms of drug-induced ILD and appropriate evidence-based strategies that can be used to prevent or manage these events.

PMID:
19305103
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
    Loading ...
    Support Center